HTFL Heartflow, Inc. Common Stock
USHealthcareAs of 2026-07-10 16:00
Why HTFL matters now
Heartflow, Inc. Common Stock (HTFL) is a US stock in Healthcare. The latest InvestLog snapshot shows $26.72 with -3.61% on the session and $2.30B in market capitalization; recent performance reads 1-month +26.47% and YTD +15.40%.
The latest financial table shown here is Q1 2026, with revenue of $52.6M, net income of $-27.4M, and EPS of $-0.07. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.6%.
The latest indexable market news headline is "New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $37.00; recent insider activity includes Tansey Casey M filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
43.39
P/S
15.16
EV/EBITDA
-31.31
DCF Value
$-2.19
FCF Yield
-2.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.1%
Operating Margin
-35.8%
Net Margin
-58.4%
ROE
830.5%
ROA
-32.5%
ROIC
-21.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $52.6M | $-27.4M | $-0.07 |
| Q4 2025 | $49.1M | $-24.4M | $-0.07 |
| FY 2025 | $176.0M | $-116.8M | $-0.32 |
| Q3 2025 | $46.3M | $-50.9M | $-0.63 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$37.00
Target (Median)
$37.00
Target Range
$37.00 - $37.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Country
US
Exchange
—
Beta
1.91
HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.